Wealth Enhancement Advisory Services’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
Other funds holding ADMA
Wealth Enhancement Advisory Services's ADMA Position: Q3 2026 in Review
Wealth Enhancement Advisory Services reduced its ADMA Biologics (ADMA) stake by 9.9% in Q3 2026, selling an estimated $57.7K and leaving 57,017 shares worth $424K. The position accounts for ﹤0.01% of the portfolio, ranked #2996.
Wealth Enhancement Advisory Services first reported a position in ADMA in Q3 2025 and has held it in 5 quarters since. The position peaked at $438K in Q2 2026. 327 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.
- Wealth Enhancement Advisory Services held 57,017 shares of ADMA Biologics worth $424K as of Q3 2026.
- Wealth Enhancement Advisory Services sold 6,237 ADMA Biologics shares in Q3 2026, an estimated $57.7K.
- ADMA Biologics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #2996 holding.
- Wealth Enhancement Advisory Services first reported a position in ADMA Biologics in Q3 2025 and has held it in 5 quarters since.
- Wealth Enhancement Advisory Services's ADMA Biologics position peaked at $438K in Q2 2026.
- 327 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.
Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.